University of Texas's MD Anderson Cancer Center: Axi-Cel Proves Effective as First-Line Treatment for High-Risk Lymphoma
March 22, 2022
March 22, 2022
HOUSTON, Texas, March 22 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
MD Anderson-led trial is the first to evaluate front-line CAR T cell therapy for high-risk LBCL
* * *
Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T . . .
* * *
MD Anderson-led trial is the first to evaluate front-line CAR T cell therapy for high-risk LBCL
* * *
Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T . . .